CCR5 and cholangiocarcinoma: Moreover, when either Maraviroc, a CCR5 antagonist [148], or anti-CCL5 antibodies were added to conditioned medium, CCA cell motility was inhibited, suggesting that CCL5 may represent a key factor in influencing CCA biology.